The literature on the connection between obesity, metabolic syndrome, and subclinical
hypothyroidism is critically analyzed in this narrative review. These conditions are frequently …

Nonalcoholic fatty liver disease (NAFLD) is a progressive metabolic liver disease with an
unknown pathogenesis and no FDA-approved drug treatment to date. Hypothyroidism has …

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease.
NAFLD often occurs associated with endocrinopathies. Evidence suggests that endocrine …

Abstract Background and Aims Thyroid axis is currently under investigation as a therapeutic
target in metabolic dysfunction‐associated steatotic liver disease (MASLD). Thyroid function …

Background Previous studies on the association between thyroid function and non‐alcoholic
fatty liver disease (NAFLD) have contradicted. Acquired resistance to thyroid hormone …

Background Obesity and metabolic syndrome (MetS) have become urgent worldwide health
problems, predisposing patients to unfavorable myocardial status and thyroid dysfunction …

Modern lifestyle diseases remain a persistent challenge in healthcare. Currently, about 422
million people worldwide are affected by diabetes, while 1 in 8 people are living with …

Thyroid hormones may be a risk factor for the development of non-alcoholic fatty liver
disease (NAFLD) and its progression to liver fibrosis. The aim of this study is to investigate …

Obesity is a chronic and complex disease associated with metabolic, organ and endocrine
complications. In the study, we analyzed a group of 105 patients suffering from obesity …

Screening for non-alcoholic fatty liver disease (NAFLD) is key step for primary management
of fatty liver in the clinical setting. Excess weight subjects carry a greater metabolic risk even …